Zorecimeran
| Vaccine description | |
|---|---|
| Target disease | COVID-19 |
| Type | mRNA |
| Clinical data | |
| Synonyms | CVnCoV |
| Routes of administration | Intramuscular |
| Identifiers | |
| DrugBank | |
| E number | {{#property:P628}} |
| ECHA InfoCard | {{#property:P2566}} |
| Part of a series on the |
| COVID-19 pandemic |
|---|
 |
|
|
|
International response |
|
Medical response |
|
Zorecimeran, also known as CVnCoV is a COVID-19 vaccine candidate developed by CureVac and Coalition for Epidemic Preparedness Innovations (CEPI).
Description[edit]
Zorecimeran is an mRNA technology programmed with information about the coronavirus protein as an unknown pathogen, and activates the immune system against it.[1] As an mRNA vaccine, zorecimeran has established safety, and provides a minimal, harmless piece of the coronavirus spike protein to initiate an immune response against COVID-19 disease.[1][2] Zorecimeran technology does not interact with the human genome.[1]
Clinical trial progress[edit]
Phase I-II[edit]
In November 2020, CureVac reported results of a Phase I-II clinical trial that zorecimeran (CVnCoV) was well-tolerated, safe, and produced a robust immune response.[3][4]
Phase III[edit]
In December, CureVac began a Phase III clinical trial of zorecimeran with 36,500 participants.[5][6][6] Bayer will provide clinical trial support and international logistics for the Phase III trial, and may be involved in eventual manufacturing should the vaccine prove to be safe and effective.[7]
Manufacturing[edit]
Manufacturing of mRNA vaccines can be performed rapidly in high volume,[8] including use of portable, automated printers ("RNA microfactories") for which CureVac has a joint development partnership with Tesla.[9]
Cold chain[edit]
mRNA vaccines require stringent cold chain refrigeration throughout manufacturing, distribution and storage.[10][11] The CureVac technology for zorecimeran uses a non-modified, more natural mRNA less affected by hydrolysis, enabling storage at 5 °C (41 °F) and relatively simplified cold chain requirements that facilitate up to three months of storage and distribution to world regions that do not have specialized ultracold equipment.[1][8]
Preorders[edit]
CureVac has a European-based network to accelerate manufacturing of zorecimeran, if proven safe and effective, for production of up to 300 million doses in 2021 and 600 million doses in 2022.[8][12] An estimated 405 million doses will be provided to EU states.[12]
References[edit]
- ↑ 1.0 1.1 1.2 1.3 Schlake, Thomas; Thess, Andreas; Fotin-Mleczek, Mariola; Kallen, Karl-Josef (2012). "Developing mRNA-vaccine technologies". RNA Biology. 9 (11): 1319–1330. doi:10.4161/rna.22269. ISSN 1547-6286. PMC 3597572. PMID 23064118.
- ↑ "Understanding mRNA COVID-19 vaccines". US Centers for Disease Control and Prevention. 18 December 2020. Retrieved 5 January 2021.
- ↑ "CureVac's Covid-19 vaccine induces immune response in study". Clinical Trials Arena. 3 November 2020. Retrieved 5 January 2021.
- ↑ "CureVac's COVID-19 vaccine triggers immune response in Phase I trial". Reuters. 2 November 2020. Retrieved 5 January 2021.
- ↑ "Multicenter Clinical Study Evaluating the Efficacy and Safety of Investigational SARS-CoV-2 mRNA Vaccine CVnCoV in Adults 18 Years of Age and Older". EU Clinical Trials Register. 19 November 2020. Retrieved 5 January 2021.
Proposed INN: "Zorecimeran"
- ↑ 6.0 6.1 "A Study to Determine the Safety and Efficacy of SARS-CoV-2 mRNA Vaccine CVnCoV in Adults". ClinicalTrials.gov. 8 December 2020. NCT04652102. Retrieved 19 December 2020.
- ↑ Ludwig Burger (6 January 2021). "CureVac strikes COVID-19 vaccine alliance with Bayer". Reuters. Retrieved 7 January 2021.
- ↑ 8.0 8.1 8.2 Allie Nawrat (3 December 2020). "Q&A with CureVac: resolving the ultra-cold chain logistics of Covid-19 mRNA vaccines". Pharmaceutical Technology. Retrieved 5 January 2021.
- ↑ "Tesla to make molecule printers for German COVID-19 vaccine developer CureVac". Reuters. 2 July 2020. Retrieved 19 December 2020.
- ↑ Kartoglu, Umit; Milstien, Julie (28 May 2014). "Tools and approaches to ensure quality of vaccines throughout the cold chain". Expert Review of Vaccines. 13 (7): 843–54. doi:10.1586/14760584.2014.923761. ISSN 1476-0584. PMC 4743593. PMID 24865112.
- ↑ Hanson, Celina M.; George, Anupa M.; Sawadogo, Adama; Schreiber, Benjamin (19 April 2017). "Is freezing in the vaccine cold chain an ongoing issue? A literature review". Vaccine. 35 (17): 2127–33. doi:10.1016/j.vaccine.2016.09.070. ISSN 0264-410X. PMID 28364920.
- ↑ 12.0 12.1 Fraiser Kansteiner (17 November 2020). "CureVac, armed with COVID-19 vaccine deal, plots 'pandemic-scale' Euro manufacturing expansion". FiercePharma, Questex LLC. Retrieved 5 January 2021.
External links[edit]
This article "Zorecimeran" is from Wikipedia. The list of its authors can be seen in its historical and/or the page Edithistory:Zorecimeran. Articles copied from Draft Namespace on Wikipedia could be seen on the Draft Namespace of Wikipedia and not main one.
